DenpaNews In an effort to suppress COVID-19 , experts do not stop innovating to create drugs that are effective in eradicating this disease. In addition to the Merck company with its newest drug, Molnupiravir , Pfizer recently released the results of a clinical trial of its COVID-19 drug, Paxlovid. How does it work and is it effective?
Paxlovid, Pfizer’s COVID-19 drug
Paxlovid belongs to a class antivirals called protease inhibitors. This drug is available in pill form that must be taken orally or taken by mouth.
The drug, developed by the Pfizer trademark, is aimed specifically at blocking an enzyme that the SARS-CoV-2 virus needs to multiply.
The beginning of the development of this drug began with Pfizer’s flashback in creating a drug to fight SARS infection in 2003. From there, researchers found that one of the drugs worked effectively against the COVID-19 virus.
Read Also :
- COVID-19 Booster Vaccine, How is it Different from Ordinary Vaccines?
- The Facts About The Omicron COVID-19 Variant
- COVID-19 Transmission Can Occur Through Touching Items Around You
- WHO declares COVID-19 a pandemic, how to deal with it?
Pfizer then developed a new oral drug candidate that works specifically against the COVID-19 virus, named PF-07321332.
How Paxlovid works
Protease inhibitor drugs such as Paxlovid work by preventing the replication or formation of large amounts of the virus.
The trick is to stop the ability of enzymes in the virus to break down proteins. This protein breakdown process is what makes the virus replicate and multiply.
Inhibiting viral replication is expected to slow or even prevent infection from occurring because the amount of virus in the body remains low. Thus, the immune system can prevent the body from experiencing severe symptoms due to COVID-19 infection.
This Article Related Too :
- Antidotes To Avoid The Side Effects Of Antibiotics
- An antibiotic of The Past to Fight Bacterial Resistance
Are Pfizer drugs effective against COVID-19?
Based on the results of clinical trials released by Pfizer , the oral drug Paxlovid was found to be effective in reducing the severity of COVID-19 symptoms, the risk of hospitalization, and preventing death.
Results from phase 2 and 3 clinical trials conducted by Pfizer show that the drug is nearly 90% effective in preventing disease severity.
The clinical trial involved 1,200 participants with COVID-19 infection who were at risk for severe symptoms, such as having risk factors such as obesity and the elderly. In the study, participants were given the drug Paxlovid and a placebo .
The result, participants who took the medicine Paxlovid had a reduced risk of hospitalization and death when compared to participants who took the placebo drug. A placebo is a blank drug that is used as a comparison or test of the actual effectiveness of the drug. Should be children vaccinanted?
Reportedly none of the participants died during the 28 days after treatment with Paxlovid. However, as many as 10 participants who received the placebo drug were declared dead.
The effectiveness of the drug will increase if given as early as possible. Clinical trial results show that administering the drug within 5 days of the first symptoms appearing reduces the risk of hospitalization by as much as 50%.
Another good news, clinical trials by Pfizer also show that the drug Paxlovid is effective against various variants of COVID-19 , especially the variant of concern (VOC) type.
So far, no severe side effects have been reported from the use of the drug Paxlovid. Participants who received this drug generally experienced mild side effects, such as nausea, vomiting, and diarrhea. In addition, the safety of this drug for pregnant and lactating women is also not known.
However, experts stress that the presence of a drug like Paxlovid will not end the COVID-19 pandemic. One of the main keys to solving a pandemic is by giving vaccinations to achieve herd immunity in a group.
Will Pfizer’s COVID-19 medicine be available in United State?
For now, Pfizer is applying for a permit from the Food and Drug Administration (FDA) in the United States. The goal is for this drug to be distributed for emergency use.
The plan is that Pfizer will allow drug manufacturers to manufacture and supply generic versions of this experimental COVID-19 antiviral pill to 95 low- and middle-income countries. This is stated in a licensing agreement with an international public health group, the Medicines Patens Pool or MPP.
Pfizer is also ready to disburse around US$1 million to support the manufacturing and distribution of this COVID-19 drug. The fund covers the search for drug manufacturing options in middle and low income countries. That way, it is hoped that this drug can be easily accessed in these countries.
Until now, it is not known whether the United State government will supply the drug Paxlovid for the treatment of COVID-19 . The reason is, there is no further information related to licensing issues and the price range of drugs. How we know life after coronavirus? or you can read Top Tips Effective Your Healthy for prevent covid19